List view / Grid view
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
31 March 2014 | By Novartis
Novartis announced that the Data Monitoring Committee unanimously recommended early closure of the PARADIGM-HF study...
21 March 2014 | By Novartis
Novartis announced that the Joint Committee on Vaccination and Immunisation in the UK has recommended the inclusion of Bexsero® (Meningococcal Group B Vaccine...
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
13 March 2014 | By Novartis
Novartis has announced that Australia has joined the growing number of countries where following licensure, Bexsero® has received a clinical recommendation...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...
28 February 2014 | By Novartis
Novartis joins the global rare disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need...
26 February 2014 | By Novartis
Novartis announced additional steps to extend its leadership in clinical trial data transparency...
25 February 2014 | By Novartis
A strong majority of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting...
24 February 2014 | By Novartis
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7...
21 February 2014 | By Novartis
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema, a leading cause of vision loss among patients with diabetes...
19 February 2014 | By Novartis
Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment...
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
